Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer
Alan P. Venook(University of California, San Francisco), Charles D. Blanke(SWOG Cancer Research Network), Howard S. Höchster(Rutgers, The State University of New Jersey), Monica M. Bertagnolli(National Institutes of Health), Jeffrey A. Meyerhardt(CancerCare), Al B. Benson(Northwestern University), Richard L. Schilsky(American Society of Clinical Oncology), Briant Fruth(Mayo Clinic), Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center), Federico Innocenti(AbbVie (United States)), Robert J. Mayer(Applied Natural Sciences), Peter J. Watson(Kinston Medical Specialists), Blasé N. Polite(Sidney Kimmel Cancer Center), Donna Niedzwiecki(Duke University), Eileen M. O’Reilly(Memorial Sloan Kettering Cancer Center), Richard M. Goldberg(Ontario Institute for Cancer Research), Scott Berry, Claire Greene(University of California, San Francisco), Daniel Mulkerin(University of Wisconsin–Madison), Deborah Schrag(Dana-Farber Brigham Cancer Center), Bert H. O’Neil(Indiana University Health), James N. Atkins(Southeastern Medical Oncology Center), Anthony B. El-Khoueiry(USC Norris Comprehensive Cancer Center)
Cited by 891
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
How To Build and Interpret a Nomogram for Cancer Prognosis
|Journal of Clinical Oncology|2008|3.4k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k